REFERENCES



Choose an author or browse all
Choose the species or browse all
Choose a criteria for sorting
 Reverse sorting
Search for a protein
Search for a single PMID
Select O-GlcNAc references filter

Click to expand (6 results)


Denis M, Dupas T, Persello A, Dontaine J, Bultot L, Betus C, Pelé T, Dhot J, Erraud A, Maillard A, Montnach J, Leroux AA, Bigot-Corbel E, Vertommen D, Rivière M, Lebreton J, Tessier A, Waard M, Bertrand L, Rozec B, Lauzier B. An O-GlcNAcylomic Approach Reveals ACLY as a Potential Target in Sepsis in the Young Rat. International journal of molecular sciences 2021 22(17) 34502162
Abstract:
Sepsis in the young population, which is particularly at risk, is rarely studied. O-GlcNAcylation is a post-translational modification involved in cell survival, stress response and metabolic regulation. O-GlcNAc stimulation is beneficial in adult septic rats. This modification is physiologically higher in the young rat, potentially limiting the therapeutic potential of O-GlcNAc stimulation in young septic rats. The aim is to evaluate whether O-GlcNAc stimulation can improve sepsis outcome in young rats. Endotoxemic challenge was induced in 28-day-old rats by lipopolysaccharide injection (E. Coli O111:B4, 20 mg·kg-1) and compared to control rats (NaCl 0.9%). One hour after lipopolysaccharide injection, rats were randomly assigned to no therapy, fluidotherapy (NaCl 0.9%, 10 mL·kg-1) ± NButGT (10 mg·kg-1) to increase O-GlcNAcylation levels. Physiological parameters and plasmatic markers were evaluated 2h later. Finally, untargeted mass spectrometry was performed to map cardiac O-GlcNAcylated proteins. Lipopolysaccharide injection induced shock with a decrease in mean arterial pressure and alteration of biological parameters (p < 0.05). NButGT, contrary to fluidotherapy, was associated with an improvement of arterial pressure (p < 0.05). ATP citrate lyase was identified among the O-GlcNAcylated proteins. In conclusion, O-GlcNAc stimulation improves outcomes in young septic rats. Interestingly, identified O-GlcNAcylated proteins are mainly involved in cellular metabolism.
O-GlcNAc proteins:
A0A096MJ01, A0A096MK30, A0A096MKD4, A0A096P6L8, A0A0G2JSH9, A0A0G2JSP8, A0A0G2JSR0, A0A0G2JSU7, A0A0G2JSW3, A0A0G2JTG7, A0A0G2JTP6, A0A0G2JUT0, A0A0G2JV65, A0A0G2JVG3, A0A0G2JVH4, A0A0G2JW41, A0A0G2JW94, A0A0G2JWK2, A0A0G2JWS2, A0A0G2JYK0, A0A0G2JZF0, A0A0G2K0F5, A0A0G2K3K2, A0A0G2K3Z9, A0A0G2K401, A0A0G2K477, A0A0G2K5I9, A0A0G2K5P5, A0A0G2K654, A0A0G2K719, A0A0G2K7F7, A0A0G2K8H0, A0A0G2K9P4, A0A0G2K9Q9, A0A0G2KAK2, A0A0G2KB63, A0A0H2UHM5, A0A0H2UHQ9, A0A0H2UHZ6, A0A0H2UI36, A0A0U1RRV7, ROA2, B0BNG3, CAH1, SCOT1, B2RYW3, C0JPT7, D3ZCV0, D3ZG43, D3ZIC4, D3ZQM0, D3ZUB0, D3ZZ68, D3ZZN3, D4A0T0, D4A5E5, D4A6Q4, SYNP2, D4A7X7, D4A8X8, D4AA63, D4ACC2, F1LM30, F1LM47, F1LMP9, F1LMV6, F1LP05, F1LP30, F1LSC3, F1LX07, F1LZW6, F1M3H8, F1M820, F1M865, F1M944, F1M953, F1MAA7, F1MAF7, G3V6E1, G3V6H0, G3V6H5, G3V6P7, G3V6S0, G3V6T7, G3V6Y6, G3V7C6, G3V7J0, G3V826, G3V885, G3V8B0, G3V8L3, G3V8V3, G3V9A3, G3V9U2, M0R5J4, M0R735, M0R757, M0R7S5, M0R9L0, PRDX6, C1QBP, HSPB2, ACOT2, HCD2, PARK7, MDHC, AATM, HBA, FIBG, GPX1, ROA1, MDHM, LDHA, PDIA1, G3P, GSTP1, ALDOA, EF2, AT1A1, BIP, RPN1, ODP2, MLRV, KCRS, HS71A, ATPB, CLH1, AT2A2, DMD, ALDH2, KPYM, AL1A7, ETFA, A1I3, CAH3, FIBB, ECHM, ACADL, PGAM2, MYL3, PGK1, ACLY, THIL, ACSL1, CPT2, CSK21, NDUV2, AT5F1, NDKB, NB5R3, IGG2A, IGG2B, LAC2, UCRI, SDHB, TNNI3, CRYAB, PPIB, PGAM1, RPN2, CAH2, TCPA, VIME, PEBP1, ATP5H, EZRI, QCR2, HS90B, 1433B, ATPG, CRIP2, RSSA, CAV1, LDHB, HSPB1, COF1, TERA, DPYL2, TPIS, DESM, ODPB, TNNT2, AL1A1, ES1, IDHP, MYPC, PSA6, ARF3, 1433G, 1433E, EF1A2, H4, RAN, RS3, AP2B1, RL40, HSP7C, CH60, PHB, ACTC, 1433T, TBA1A, 1433F, TBB5, NUP54, VDAC2, HS90A, EFTU, PNPH, HSPB6, PTBP1, H2B1, MUG1, ATPO, ANXA2, ADT2, K2C8, PRRC1, NIT2, Q498N4, ACSF2, H2A3, K2C6A, Q4G079, AGFG1, Q4PP99, Q4V8E1, EHD2, Q52KS1, NDUAA, Q5BJZ3, Q5D059, Q5M9H2, Q5RJN0, Q5RJR9, UBA1, Q5XFV4, LPP, Q5XI38, GDIR1, ODO1, TBA4A, Q5XIH3, ECHB, PDLI5, A1M, CPT1B, NDUS2, ECHA, ENPL, NDUS1, Q66HF3, MAVS, AMPL, ETFB, QCR1, K1C42, Q6IFU9, K1C14, K1C15, K1C13, K1C10, K2C75, K2C1, HNRPU, Q6IMZ3, TS101, RAB1A, PLAK, K2C5, DLDH, SYWC, TBA1B, Q6P9Y4, Q6PDV6, CNDP2, ROA3, CACP, DEST, Q7TQ70, CISY, Q91XN6, SDHA, IDH3A, ACON, AIFM1, MYG, TGM2, HCDH, VDAC1, SC31A
Download
Ma J, Banerjee P, Whelan SA, Liu T, Wei AC, Ramirez-Correa G, McComb ME, Costello CE, O'Rourke B, Murphy A, Hart GW. Comparative Proteomics Reveals Dysregulated Mitochondrial O-GlcNAcylation in Diabetic Hearts. Journal of proteome research 2016 15(7) 27213235
Abstract:
O-linked β-N-acetylglucosamine (O-GlcNAc), a post-translational modification on serine and threonine residues of many proteins, plays crucial regulatory roles in diverse biological events. As a nutrient sensor, O-GlcNAc modification (O-GlcNAcylation) on nuclear and cytoplasmic proteins underlies the pathology of diabetic complications including cardiomyopathy. However, mitochondrial O-GlcNAcylation, especially in response to chronic hyperglycemia in diabetes, has been poorly explored. We performed a comparative O-GlcNAc profiling of mitochondria from control and streptozotocin (STZ)-induced diabetic rat hearts by using an improved β-elimination/Michael addition with isotopic DTT reagents (BEMAD) followed by tandem mass spectrometric analysis. In total, 86 mitochondrial proteins, involved in diverse pathways, were O-GlcNAcylated. Among them, many proteins have site-specific alterations in O-GlcNAcylation in response to diabetes, which suggests that protein O-GlcNAcylation is a novel layer of regulation mediating adaptive changes in mitochondrial metabolism during the progression of diabetic cardiomyopathy.
Download
Ma J, Liu T, Wei AC, Banerjee P, O'Rourke B, Hart GW. O-GlcNAcomic Profiling Identifies Widespread O-Linked β-N-Acetylglucosamine Modification (O-GlcNAcylation) in Oxidative Phosphorylation System Regulating Cardiac Mitochondrial Function. The Journal of biological chemistry 2015 290(49) 26446791
Abstract:
Dynamic cycling of O-linked β-N-acetylglucosamine (O-GlcNAc) on nucleocytoplasmic proteins serves as a nutrient sensor to regulate numerous biological processes. However, mitochondrial protein O-GlcNAcylation and its effects on function are largely unexplored. In this study, we performed a comparative analysis of the proteome and O-GlcNAcome of cardiac mitochondria from rats acutely (12 h) treated without or with thiamet-G (TMG), a potent and specific inhibitor of O-GlcNAcase. We then determined the functional consequences in mitochondria isolated from the two groups. O-GlcNAcomic profiling finds that over 88 mitochondrial proteins are O-GlcNAcylated, with the oxidative phosphorylation system as a major target. Moreover, in comparison with controls, cardiac mitochondria from TMG-treated rats did not exhibit altered protein abundance but showed overall elevated O-GlcNAcylation of many proteins. However, O-GlcNAc was unexpectedly down-regulated at certain sites of specific proteins. Concomitantly, TMG treatment resulted in significantly increased mitochondrial oxygen consumption rates, ATP production rates, and enhanced threshold for permeability transition pore opening by Ca(2+). Our data reveal widespread and dynamic mitochondrial protein O-GlcNAcylation, serving as a regulator to their function.
Download
Hu Y, Suarez J, Fricovsky E, Wang H, Scott BT, Trauger SA, Han W, Hu Y, Oyeleye MO, Dillmann WH. Increased enzymatic O-GlcNAcylation of mitochondrial proteins impairs mitochondrial function in cardiac myocytes exposed to high glucose. The Journal of biological chemistry 2009 284(1) 19004814
Abstract:
Increased nuclear protein O-linked beta-N-acetylglucosamine glycosylation (O-GlcNAcylation) mediated by high glucose treatment or the hyperglycemia of diabetes mellitus contributes to cardiac myocyte dysfunction. However, whether mitochondrial proteins in cardiac myocytes are also submitted to O-GlcNAcylation or excessive O-GlcNAcylation alters mitochondrial function is unknown. In this study, we determined if mitochondrial proteins are O-GlcNAcylated and explored if increased O-GlcNAcylation is linked to high glucose-induced mitochondrial dysfunction in neonatal rat cardiomyocytes. By immunoprecipitation, we found that several mitochondrial proteins, which are members of complexes of the respiratory chain, like subunit NDUFA9 of complex I, subunits core 1 and core 2 of complex III, and the mitochondrial DNA-encoded subunit I of complex IV (COX I) are O-GlcNAcylated. By mass spectrometry, we identified that serine 156 on NDUFA9 is O-GlcNAcylated. High glucose treatment (30 mm glucose) increases mitochondrial protein O-GlcNAcylation, including those of COX I and NDUFA9 which are reduced by expression of O-GlcNAcase (GCA). Increased mitochondrial O-GlcNAcylation is associated with impaired activity of complex I, III, and IV in addition to lower mitochondrial calcium and cellular ATP content. When the excessive O-GlcNAc modification is reduced by GCA expression, mitochondrial function improves; the activity of complex I, III, and IV increases to normal and mitochondrial calcium and cellular ATP content are returned to control levels. From these results we conclude that specific mitochondrial proteins of cardiac myocytes are O-GlcNAcylated and that exposure to high glucose increases mitochondrial protein O-GlcNAcylation, which in turn contributes to impaired mitochondrial function.
O-GlcNAc proteins:
COX1, NDUA9, QCR1
Download
Clark PM, Dweck JF, Mason DE, Hart CR, Buck SB, Peters EC, Agnew BJ, Hsieh-Wilson LC. Direct in-gel fluorescence detection and cellular imaging of O-GlcNAc-modified proteins. Journal of the American Chemical Society 2008 130(35) 18683930
Abstract:
We report an advanced chemoenzymatic strategy for the direct fluorescence detection, proteomic analysis, and cellular imaging of O-GlcNAc-modified proteins. O-GlcNAc residues are selectively labeled with fluorescent or biotin tags using an engineered galactosyltransferase enzyme and [3 + 2] azide-alkyne cycloaddition chemistry. We demonstrate that this approach can be used for direct in-gel detection and mass spectrometric identification of O-GlcNAc proteins, identifying 146 novel glycoproteins from the mammalian brain. Furthermore, we show that the method can be exploited to quantify dynamic changes in cellular O-GlcNAc levels and to image O-GlcNAc-glycosylated proteins within cells. As such, this strategy enables studies of O-GlcNAc glycosylation that were previously inaccessible and provides a new tool for uncovering the physiological functions of O-GlcNAc.
Park J, Kwon H, Kang Y, Kim Y. Proteomic analysis of O-GlcNAc modifications derived from streptozotocin and glucosamine induced beta-cell apoptosis. Journal of biochemistry and molecular biology 2007 40(6) 18047804
Abstract:
The post-translational modifications of Ser and Thr residues by O-linked beta-N-acetylglucosamine (O-GlcNAc), i.e., O-GlcNAcylation, is considered a key means of regulating signaling, in a manner analogous to protein phosphorylation. Furthermore, it has been suggested that the increased flux of glucose through the hexosamine biosynthetic pathway (HBP) stimulates O-GlcNAcylation, and that this may be responsible for many of the manifestations of type 2 diabetes mellitus. To determine whether excessive O-GlcNAcylation of target proteins results in pancreatic beta cell dysfunction, we increased nucleocytoplasmic protein O-GlcNAcylation levels in beta cells by exposing them to streptozotocin and/or glucosamine. Streptozotocin and glucosamine co-treatment increased OGlcNAcylated proteomic patterns as assessed by immunoblotting, and these increases in nuclear and cytoplasmic protein O-GlcNAcylations were accompanied by impaired insulin secretion and enhanced apoptosis in pancreatic beta cells. This observed beta cell dysfunction prompted us to examine Akt and Bcl-2 family member proteins to determine which proteins are O-GlcNAcylated under conditions of high HBP throughput, and how these proteins are associated with beta cell apoptosis. Eventually, we identified ten new O-GlcNAcylated proteins that were expressed during beta cell apoptosis, and analyzed the functional implications of these proteins in relation to pancreatic beta cell dysfunction.
O-GlcNAc proteins:
ENOA, PDIA1, EF2, KCRB, ATPB, RSSA, TERA, ANXA4, CH60, ACTG, TBB5, K2C8, TCPE, QCR1, CLIC1, Q6P3V8, IDH3A
Download
Page 1 of 1